ArticleScientific reports2025
Correlation analysis between RAS gene mutations and pathological morphological features in colorectal cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To examine associations between Kirsten rat sarcoma viral oncogene (KRAS) mutations and histopathological features in colorectal cancer and to evaluate their prognostic implications. A total of 256 patients with colorectal adenocarcinoma treated between January 2018 and December 2022 were retrospectively included. Rat sarcoma (RAS) gene mutations, covering 21 sites in KRAS and NRAS, were detected using the ADx-ARMS kit. Due to the low mutation rate of NRAS (3.9%) and its lack of significant correlation with pathological features (P > 0.05), further analysis focused on KRAS mutations. Tumor differentiation, mucinous components, and tumor budding were assessed by two pathologists in a double-blind manner. The relationship between KRAS mutation status and morphological features was analyzed using logistic regression, and the prognostic value was evaluated using the Cox proportional hazards model. The KRAS mutation rate was 52.7% (135/256), with the main subtypes being G12D (30.37%), G13D (20.00%), G12V (17.78%), and G12C (7.41%). Logistic regression showed that KRAS mutation independently predicted right-sided colon tumors (OR = 1.85, P = 0.017), high tumor budding (OR = 2.46, P = 0.002), and mucinous components (OR = 2.39, P = 0.012). It was also positively associated with PIK3CA co-mutation (OR = 2.15, P = 0.042). Overall survival (OS) was longer in patients with KRAS mutations than in those with wild-type KRAS (P = 0.013), was longer in KRAS-mutated than wild-type cases (P = 0.013), whereas progression-free survival (PFS) showed no significant difference. No survival differences were detected among KRAS subtypes. Multivariate Cox analysis showed that TNM stage IV (HR = 4.80), poor differentiation (HR = 2.00), and absence of primary tumor resection (HR = 3.20) were independent adverse prognostic factors. KRAS mutations are closely associated with aggressive pathological features in colorectal cancer, particularly tumor budding and mucinous differentiation. Histopathological evaluation may aid risk stratification alongside KRAS status. Prognostic assessment in clinical settings should take both TNM staging and KRAS status into account.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.